Ids
stringlengths 36
36
| text
stringlengths 45
2.03k
| label
int64 0
1
|
|---|---|---|
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: No progression of extra-CNS disease as assessed by RECIST secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length. secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+) secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days. secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only secondary trial: Unit of Measure: percentage of subjects 35 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Objective Response Rate (ORR) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Time frame: Up to 2 years. the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Arm/Group Title: NKTR-102 14 Day the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Measure Type: Number the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3) the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Arm/Group Title: NKTR-102 21 Days the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |
bd073d05-3ba2-4898-9d86-a51951a7ad1f | primary trial: *8mg/kg loading dose in cycle 1 for some participants secondary trial: Overall Number of Participants Analyzed: 35 the primary trial and the secondary trial both use tumor Objective response rate to measure the effects of their different interventions. | 0 |